Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
4.320
-0.020 (-0.46%)
Apr 24, 2026, 4:00 PM EDT - Market closed
Coya Therapeutics Revenue
In the year 2025, Coya Therapeutics had annual revenue of $7.95M with 123.57% growth. Coya Therapeutics had revenue of $3.96M in the quarter ending December 31, 2025, with 202,768.80% growth.
Revenue (ttm)
$7.95M
Revenue Growth
+123.57%
P/S Ratio
12.75
Revenue / Employee
$993,219
Employees
8
Market Cap
101.34M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.95M | 4.39M | 123.57% |
| Dec 31, 2024 | 3.55M | -2.45M | -40.79% |
| Dec 31, 2023 | 6.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rani Therapeutics Holdings | 1.63M |
| Coeptis Therapeutics Holdings | 1.36M |
| NRx Pharmaceuticals | 1.23M |
| Inovio Pharmaceuticals | 65.34K |
| InflaRx | 34.44K |
| Fractyl Health | 3.00K |
COYA News
- 17 days ago - Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS - Business Wire
- 24 days ago - Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director - Business Wire
- 5 weeks ago - Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy - Business Wire
- 5 weeks ago - Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results - Business Wire
- 2 months ago - Coya Therapeutics Transcript: Status update - Transcripts
- 2 months ago - Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial - Business Wire
- 3 months ago - Coya Therapeutics Announces $11.1 Million Private Placement - Business Wire
- 3 months ago - Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders - Business Wire